S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
NASDAQ:ATXS

Astria Therapeutics (ATXS) Stock Price, News & Analysis

$9.75
-0.79 (-7.50%)
(As of 04/19/2024 08:50 PM ET)
Today's Range
$9.48
$10.64
50-Day Range
$9.75
$16.69
52-Week Range
$4.26
$16.90
Volume
1.24 million shs
Average Volume
974,579 shs
Market Capitalization
$535.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.75

Astria Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
123.1% Upside
$21.75 Price Target
Short Interest
Bearish
11.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Astria Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$30 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.55) to ($1.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.77 out of 5 stars

Medical Sector

658th out of 908 stocks

Pharmaceutical Preparations Industry

292nd out of 414 stocks

ATXS stock logo

About Astria Therapeutics Stock (NASDAQ:ATXS)

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

ATXS Stock Price History

ATXS Stock News Headlines

Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
ATXS Apr 2024 2.500 put
ATXS Oct 2024 22.500 call
ATXS Mar 2024 22.500 call
ATXS Mar 2024 12.500 call
See More Headlines
Receive ATXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/04/2024
Today
4/22/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ATXS
Employees
59
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$21.75
High Stock Price Target
$27.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+123.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-72,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.33 per share

Miscellaneous

Free Float
53,036,000
Market Cap
$535.28 million
Optionable
Optionable
Beta
0.69

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Ms. Jill C. Milne Ph.D. (Age 56)
    Co-Founder, CEO, President & Director
    Comp: $928.52k
  • Mr. Benjamin S. Harshbarger J.D. (Age 55)
    Chief Legal Officer
    Comp: $621.91k
  • Mr. Noah C. Clauser CPA (Age 50)
    CFO & Treasurer
    Comp: $508.79k
  • Ms. Keri McGrail
    Senior Vice President of Human Resources
  • Ms. Andrea L. Matthews
    Chief Business Officer
  • Mr. Andrew A. KomjathyMr. Andrew A. Komjathy (Age 60)
    Chief Commercial Officer
  • Dr. Christopher J. Morabito M.D. (Age 53)
    Chief Medical Officer
  • Mr. John Ruesch
    Senior Vice President of Pharmaceutical Sciences & Technical Operations

ATXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Astria Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Astria Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATXS shares.
View ATXS analyst ratings
or view top-rated stocks.

What is Astria Therapeutics' stock price target for 2024?

4 brokers have issued 12 month price targets for Astria Therapeutics' shares. Their ATXS share price targets range from $17.00 to $27.00. On average, they predict the company's stock price to reach $21.75 in the next year. This suggests a possible upside of 123.1% from the stock's current price.
View analysts price targets for ATXS
or view top-rated stocks among Wall Street analysts.

How have ATXS shares performed in 2024?

Astria Therapeutics' stock was trading at $7.68 on January 1st, 2024. Since then, ATXS shares have increased by 27.0% and is now trading at $9.75.
View the best growth stocks for 2024 here
.

When is Astria Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ATXS earnings forecast
.

How were Astria Therapeutics' earnings last quarter?

Astria Therapeutics, Inc. (NASDAQ:ATXS) announced its quarterly earnings data on Monday, March, 4th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by $0.08.

When did Astria Therapeutics' stock split?

Astria Therapeutics's stock reverse split before market open on Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of Astria Therapeutics?

Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATXS) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners